Salermide

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP19469CAS No. ：1105698-15-4Purity：98%

Get Quotation Now

Tel: 0086-13026320035 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	1105698-15-4	Cat. No.	BCP19469
Name	Salermide
Synonyms
SMILES
Chemical Name
Formula	C26H22N2O2	M. Wt	394.47
Purity	98%	Storage	Store at 4-8°C
Description	InVitro: Salermide shows a dose-dependent inhibition that rises to 80% at 90 μM and 25 μM against Sirt1 and Sirt2, respectively. Salermide can prompt tumour-specific cell death in a wide range of human cancer cell lines derived from leukaemia (MOLT4, KG1A, K562), lymphoma (Raji), colon (SW480) and breast (MDA-MB-231). Incubation with 100 μM Salermide alone results in an increase of cytosolicactivated caspase 3 and a decrease of mitochondrialcytochrome. Salermide alone can induce apoptosis through both extrinsic and intrinsic pathways. Salermide had several antitumorigenic advantages over the earlier described class III HDAC inhibitors: firstly, it mimics the universal proapoptotic effect on cancer samples exhibited by the classical class I, II and IV HDAC inhibitors, and secondly, its proapoptotic effect is cancer-specific. InVivo: Salermide is well tolerated by mice at concentrations up to 100 μM. Salermide's mechanism of action in vivo is specifically mediated by Sirt1. Intraperitone